

Statistics on R&D Activities 2010



dentification of the organi	sation or centre		
mendments to the identifica	tion particulars (Cor	mplete only those see	ctions subject to variation)
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	
ame of the organisation or centre	_	_	NIF
anie of the organisation of centre			IVII
egistered address (street, square, avenue, etc.)			
ostal code Municipality			
rovince P	Provincial code Telephone	Fax	E-mail
etails of the person to be contacted, i		aina	SIGNATURE OR SEAL
eries, clarifications or modifications		laire.	
r./Ms.:			
st held:			
elephone	Fax:		
mail:			
lehsite:			

Nature, characteristics and purpose

These statistics are within the framework of the General plan for statistics on science and technology promoted by the Statistics Office of the European Union (Eurostat). They have the main objective of ascertaining the resources that research organisations and centres spend on R&D, for the purpose of estimating the national effort in research.

They are conducted following recommendations of the OECD (Frascati Manual).

Statistical Legislation of compulsory compliance

Statistical Secrecy

The personal information obtained by the statistical services, both directly from the informants and from administrative sources, shall be subject to protection, and covered by **statistical secrecy** (article 13.1 of the Law on Public Statistical Services, of 9 May 1989, (LFEP)). All statistical staff will be obliged to maintain statistical secrecy (article 17.1 of the LFEP).

Obligation to provide data

Laws 4/1990 and 13/1996 establish the obligation to provide the data that is requested for the compilation of these Statistics.

The statistical services may request data from all individuals and companies, regardless of whether they are Spanish or foreign, resident in Spain (Article 10.1 of the LFEP).

All individuals and legal entities that provide data, regardless of whether their collaboration is compulsory or voluntary, must respond in a true, exact and comprehensive manner within the stipulated deadline to the questions outlined in due form by the statistical services (art. 10.2 of the LFEP).

In order to monitor compliance with these regulation, the LFEP (art. 48) grants the INE sanctioning capacity.

Failure to comply with the obligations envisaged in this Law, as related to statistics for state purposes, shall be sanctioned in accordance with the terms established in the regulations contained in this Heading (art. 48.1 of the LFEP).

Very serious infringements shall be sanctioned with fines ranging from 3,005.07 to 30,050.61 euros. Serious infringements shall be sanctioned with fines ranging from 300.52 to 3,005.06 euros. Minor infringements shall be sanctioned with fines ranging from 60.10 to 300.51 euros (art. 51.1, 51.2 and 51.3 of the LFEP).

General considerations

For the purposes of these statistics, the following are regarded as R&D activities: the group of creative activities undertaken systematically, in order to increase the flow of scientific and technical knowledge and use them to introduce new applications. This activity comprises basic research, applied research and experimental development. The latter leads to new devices, products, materials, processes, services or systems.

The following are not included as R&D activities: education, scientific and technical information, collection of data of a general nature, routine trials, everyday standardisation work or other technological activities relating to production or use of known products or processes. Mineral exploration is not included either, when it is aimed at discovering exploitable reserves and not essentially an increase in basic geological knowledge.

The criterion distinguishing R&D from other activities is the presence or lack of a notable degree of creativity or innovation.

General instructions

Information unit: The information that is requested in this questionnaire refers to the unit, organisation or centre whose identification data appears on the front cover. The data requested refers to all of the units dependent on this.

Reference period: Data must refer to the target year of the statistics.

Form of recording the data: Write down the data clearly. Please do not write in the shaded areas. The financial data is requested in euros with no decimals.

Consignment term: This questionnaire, duly completed with the required information, must be returned within a term not exceeding 15 days from

Please carefully read the annex before completing this questionnaire.

1. General data for the organisation	or	centre
--------------------------------------	----	--------

1.1 List of centres whose research data is included in this questionnaire	
Please enter the name, Tax Identification Number (NIF) and full address	
1	
23	
4	
5	
6	
8	
9	
1.2 Type of administration on which it depends	
Please mark where appropriate with an 'X':	
State Administration	5
Autonomous Administration	6
Local Administration (Regional Council, Municipal Council and the like)	7
PNPI* mainly controlled and/or financed by the Administration	8
(*) PNPI: Private Non-Profit Institutions.	
1.3 Institution type	
Please mark where appropriate with an 'X':	
Administrative service (of a ministry, department, regional council, municipal council, etc.)	1
Administrative autonomous organisation	2
Trade, industrial, financial or similar autonomous organisation	3
Other public law entity Specify:	4
1.4 Administrative unit immediately above, to which it responds	
Please write the full name of the administrative unit immediately above	
1.5 Functional dependency of health establishments	
Only answer this question where the research body or centre identified on the cover of the questionna (hospital, clinic, sanatorium, hospital complex, etc.). Please mark the dependency of the centre with an	
National Health Management Institute	1
Health Service of the Autonomous Community	2
Regional or Municipal Council (including Insular Council, Inter-island Council and the like)	3
Other State Administration and Social Security units	4
Other Autonomous Administration units	5
Another entity (Please specify: other jointly-managed public bodies, private charitable, private non-cha	6

2. Staff employed in internal R&D activities in 2010

2.1 Staff employed in internal R&D, according to occupation

The full-time equivalent (FTE) is the sum of the staff that works full-time and the fractions of time that the part-time staff works on R&D activities. (See annex at the end of the questionnaire).

Occupation	Total	Women	Total on FTE * (1 decimal)	Women on FTE * (1 decimal)
Researchers (including interns in research)				
2. Technicians			<u> </u>	
3. Assistants				
TOTAL STAFF (1+2+3) Out of the researchers from point 1, please indicate the interns in				·

	Staff in	Staff in R&D			chers (includ	ling interns)
Qualification	Total	Women	Total on FTE * (1 decimal)	Total	Women	Total on FTE (1 decimal)
1. University doctorate-holders						
2. University graduates, architects, engineers and the like						
3. Diploma students, technical architects and						
engineers and the like						
4. Advanced training cycles (Specific						
Vocational Training)						
5. Intermediate training cycles, Post-Secondary qualification						
and the like						
6. Other studies						
TOTAL (1+2+3+4+5+6)			<u> </u>			

2.3 Distribution of staff in internal R&D, by Autonomous Community in which the organisation or centre carries out R&D activities

	Staff in R&D				Researchers (including interns)			
Autonomous Community	Total	Women	Total on FTE * (1 decimal)	Women on FTE* (1 decimal)	Total	Women	_	Women on FTE* (1 decimal)
1. Andalucía					-			
3. Asturias (Principado de)								
4. Balears (Illes)								
5. Canarias								
7. 04:111-4								
0.0 1. 1. 1.								
9. Cataluña								
10. C								
11. Extremadura								
40.0.1::								
13. Madrid (Comunidad de)								
14. Murcia (Región de)								
15.Navarra(Comunidad Foral de)		_						
16. País Vasco						_		
10. Ct-								
TOTAL								
/*\ ETE: Eull time equivelent							_	

2.4 Researchers, by sex and age grou	All ages	Under 25 years of age	25 to 34	35 to 44 years old	45 to 54 years old	55 to 64 years old	65 years old or over
Total researchers						-	
Of them, women		·			-		
2.5 Researchers, by nationality and s	ex (includ	ding interns	in resear	ch)			
2.0 Hoseuronoro, by nationality and o	OX (IIIOIG	anig intorno	mrocour	Total rese	archers	Of them	n, women
Spain							,
Rest of the EU ¹							
Other European countries						_	
North America							
Central America							
South America							
Asia							
Africa							
Oceania						_	
TOTAL						_	
¹ Rest of the European Union: Germany, Austria, Bela	gium, Bulgari	a, Cyprus, Denm	ark, Slovakia,	Slovenia, Esto	nia, Finland, Fr	ance, Greece,	Hungary, Ireland
Italy, Latvia, Lithuania, Luxembourg, Malta, Norway,	the Netherlar	nds, Poland, Port	ugal, the Unit	ed Kingdom, th	e Czech Repub	lic, Romania aı	nd Sweden.
2.6 Staff dedicated to internal R&D a	ctivities,	oy scientific	field or d	iscipline			
		Sta	ff in R&D		Researc	hers (includi	ng interns)
		Tot	al	Women	Total		Women
1. Exact and natural sciences							
2. Engineering and technology							
3. Medical sciences							
4. Agrarian							
5. Social sciences							
6. Humanities							
TOTAL							
3. Expenditure on R&D activit	ies in 2	010					
3.1 Expenditure on internal R&D activ	vities in 2	010					
Expenditure on remunerations shall be t technicians and assistants on FTE specified percentage of the part that corresponds to F	hose corre I in 2.1. For	sponding to					
						nount (eu imals)	ıros withou
- Remunerations of researchers on FTE (inc	luding the i	emuneration	of interns)		1		
- Remunerations of technicians and assistar	nts				2		
- Other current expenses (without VAT or ar	mortization	s)			3		
A. Total current expenditure on R&D					A		
- Equipment and instruments					4		
- Land and buildings (without VAT)					5		
- Acquisition of specific software for R&D (in	ncluding lic	ences) (witho	ut VAT)		6		
B Total capital expenditure on R&D					B		
C. Total internal expenditure on R&D					С		

3.2 Financing of internal R&D expenditure in 2010

Breakdown of the total internal expenditure on R&D from question 3.1, according to the original source of the funds received for R&D. In section B. Public financing should differentiate between the origin of funds, by type of Financing Administration, including within it the budgetary resources of the organisation, subsidies, loans, contracts, etc., according to the type of administration on which it depends.

Source of the funds		Amount decimals)	(euros	without
A. Financed by the actual organisation or centre				
- (This includes patrimonial income, refundable loans and income from sales or provision of services)	1			
B. Public financing	_			
- From the State Administration and its Autonomous Institutions (AI)	1			
- From the State Administration to which it belongs (where appropriate) and its Al	2			
- From other Autonomous Administrations and their Al	3			
- From local administrations	4			
C. Other domestic sources to carry out R&D				
- From public companies	1			
- From private companies and research associations	2			
- From public universities				
- From private universities	4			
- Private Non-Profit Institutions	· 5			
D. Funds from abroad for carrying out R&D				
- From foreign companies	1			
- From the European Union				
- From foreign public administrations	3			
- From foreign universities	4			
- From foreign Private Non-Profit Institutions	5			
- From other international organisations	6			
Total internal expenditure on R&D (this must coincide				
3.3 Regionalisation of internal R&D expenditure in 2010				_
Please distribute the total internal expenditure on R&D indicated in question 3.1, according which the R&D activities have been carried out.	g to the A			
Autonomous Community		Amount decimals)	(euros	without
1. Andalucía	1			
2. Aragón	2			
3. Asturias (Principado de)	3			
4. Balears (Illes)	4			
5. Canarias	5			
6. Cantabria	6			
7. Castilla y León	7			
8. Castilla-La Mancha	8			
9. Cataluña	9			
10. Comunitat Valenciana	10			
11. Extremadura	11			
12 Galicia	12			
13. Madrid (Comunidad de)	13			
14. Murcia (Región de)	14			
15. Navarra (Comunidad Foral de)	15			
16. País Vasco	16			
17. Rioja (La)	17	-		
18. Ceuta	18			
19. Melilla	19			
Total internal expenditure on R&D (this must coincide				

1. Fundamental or basic research

2. Applied research

3.4 Socio-economic objective

Please break down, as a percentage, the expenditure on R&D that the organisation or centre has incurred in 2010, according to

		%		
1. Exploration and exploitation of the land media and of the atmosphere		1	1	9
2. Control and care of the environment		2		9
3. Exploration and exploitation of space		3		9
4.1 Transport and telecommunications systems		4.1		9
4.2 Other infrastructures		4.2		9
5. Production, distribution and rational use of energy		5		9
6. Industrial production and technology		6		9
7. Protection and improvement of human health		7		<u> </u>
8. Development of agriculture, livestock breeding, forestry and fishing 9. Education		8 _		9
10. Culture, leisure, religion and communication		10	1	1 9
11. Political and social systems, structures and processes		11	+	1 9
12. Unguided research		12	1	
13. Defence		13		1 9
TOTAL			1 0	0
			1 0	U
3.5 Research expenditure on the protection and improvement of human health If in the previous question (3.4 Socio-economic objective) there is a percentage of expenditu		Drot	tootio	n and
improvement of human health, please indicate the expenditure, according to the Autonom				
research is carried out.	iouo community in t	•••••		ouitii
(The percentage from point 7. Protection and improvement of human health, multiplied by	the total research ex	pend	iture	of the
centre, must be equal to the expenditure on research in the protection and improvement of h	uman health)			
Autonomous Community	Amount decimals)	(eur	os	witho
1. Andalucía				
2. Aragón				
3. Asturias (Principado de)				
4. Balears (IIIes)				
5. Canarias				
6. Cantabria				
7. Castilla y León				
8. Castilla-La Mancha				
9. Cataluña				
9. Cataluña 10. Comunitat Valenciana				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de)				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de)				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de)				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La)				
15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19. Melilla				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La)				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19. Melilla Total expenditure on research in the protection and improvement of human health				
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19. Melilla Total expenditure on research in the protection and improvement of human health 3.6 Research grants Please estimate the total value of the grants received in the year 2010 by the research interns	s listed in section 2.1			
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19. Melilla	s listed in section 2.1 pe included in the re	emun	erati	on of
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19. Melilla Total expenditure on research in the protection and improvement of human health 3.6 Research grants Please estimate the total value of the grants received in the year 2010 by the research internative type of grant and the organisation that has granted it to them. This figure must be	s listed in section 2.1 be included in the re		erati	
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19. Melilla Total expenditure on research in the protection and improvement of human health 3.6 Research grants Please estimate the total value of the grants received in the year 2010 by the research internst the type of grant and the organisation that has granted it to them. This figure must be researchers from question 3.1.	s listed in section 2.1 pe included in the re	emun	erati	on of
9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19. Melilla Total expenditure on research in the protection and improvement of human health 3.6 Research grants Please estimate the total value of the grants received in the year 2010 by the research internative type of grant and the organisation that has granted it to them. This figure must be	s listed in section 2.1 be included in the re Amount decimals)	emun	erati	on of

3. Experimental research TOTAL					3 1 0 0 %
3.8 Evolution of the annual	resources in scie	ntific research	and technologic	cal developm	ent activities
			tal staff on FTE* decimal)		Total internal expenditure on R&D (euros without decimals)
Resources anticipated for the ye	ar 2011				
(*) FTE: Full-time equivalent.					
3.9 Purchase of external R&	D services in 201	0			
This is caused by the acquisition		_	anication or contro	via contract	paraamant ata It daas nat
include institutional quotas for fi					
				А	mount (euros withou
A. Purchase of R&D services in S	Spain (without VAT)				ecimals)
From companiesFrom Public Administration boo	dioc			1	
- From universities				2	
- From Private Non-Profit Institut	ions			4	
B. Purchase of R&D services abr	oad (without taxes)				
- From foreign companies	ouu (out uuz.oo,			1	
- From foreign public administra	tions			2	
- From foreign universities				3	
- From foreign Private Non-Profi				4	
- From other international organ				5	
C. Total purchase of R&D service	es (A+B)				
Does the centre carry out any accorganisms or compounds obtained products of value (including biocolf the answer is YES, please complete. Please indicate the resources de The full-time equivalent (FTE) is activities based on biological sci	I from them, for the properties and nanobion the Biotechnologicated to activities but the sum of the staff.	urpose of obtaining technology)? y Use Module ased on biological if that works full-	g knowledge or sciences and technology	ons of time tha	·
Staff		Staff on FTE(1 decimal)	Total decimal	expenditure (euros withous)
Total	Women		Women	decimal	5/
Resources used:	<u> </u>				
5. Activities for Large	Scientific and	l Technolog	ical Installati	ions	
Large Scientific and Technolog partially open to use by the er particle accelerators, synchotr technology laboratories and ce	ical Installations are ntire scientific-techn on light sources, s	e unique facilities ological and indu	dedicated to cutti strial community,	ing-edge scienc , whether dome	estic or international (such a
1. Does the centre carry out any ac	ctivity for Spanish Lar	ge Scientific and T	echnological Install	ations?	YES NO
2. Does the centre carry out any ac	ctivity for internationa	ıl Large Scientific a	nd Technological Ir	nstallations?	YES NO
6. In 2010, did the org	anisation carr	y out any in	ternal R&D a	activity usi	ng or containing
Free software refers to that software freely used, copied, studied, excha	•		over the acquired p	product, and the	refore, once obtained, it can b
YES	NO				
7. How long did it tak	e to complete	this questi	onnaire?		
Including the time required to	collect the informa	ation necessary t	o do so		
				ı	1 1 1
Observations					Hours

The National Statistics Institute would like to thank you for your cooperation

1 Scientific Research and Experimental Development (R&D) Activities

1.1 Basic definitions

Scientific research and experimental development (R&D) is comprised of the creative work carried out systematically in order to increase the volume of knowledge, including the knowledge of man, culture and society, and the use of this knowledge to create new applications.

The criterion referring to creative work carried out systematically is met by projects with specific objectives and a budget.

The term R&D comprises three activities: basic research, applied research and experimental development:

- Basic research consists of experimental or theoretical work that is mainly undertaken to obtain new knowledge on the essentials of observable phenomena and facts, without considering giving them any particular application or use whatsoever.
- Applied research also consists of the original work carried out to acquire new knowledge; however, it is mainly directed towards a specific practical objective.
- •Experimental development consists of systematic work based on existing knowledge, obtained from the research and/or practical experience, aimed at the production of new materials, products or devices; at the establishment of new processes, systems and services, or at the substantial improvement of those already existing.

A **criterion** that allows R&D to be distinguished from other related activities is the existence, within the core of R&D, of an appreciable element of innovation and the resolution of a scientific and/or technological uncertainty; in other words, R&D appears when the solution to a problem is not evident to someone who is perfectly aware of the set of knowledge and basic techniques customarily used in the sector at hand.

Not constituting R&D are those activities that do not contain an appreciable element of innovation, as well as those routine activities that do not imply the resolution of a scientific or technological uncertainty.

1.2 Staff in R&D

All staff directly employed in R&D must be accounted for. as well as those persons who provide services directly related to R&D activities, such as directors, administrators and office staff.

Researchers are professionals who work on the conception or creation of new knowledge, products, processes, methods and systems, and on the management of their respective projects (it includes postgraduate students and interns who carry out R&D activities).

Technicians and/or similar personnel are persons whose main tasks require technical knowledge and experience in one or various fields of engineering, physical and life sciences, or social sciences and humanities. They participate in R&D, carrying out scientific and technical tasks that require the application of operational methods and principles, generally under the supervision of researchers.

Assistants (remaining staff) include workers, both qualified and unqualified, and secretaries and office staff, who participate in the execution of the R&D projects, or who are directly related to the execution of said projects.

1.3 Staff in R&D on FTE

The staff on full-time equivalent (FTE) is the sum of the staff that works full-time and the fractions of time that the part-time staff works on R&D activities. Therefore, a person dedicated full-time to R&D shall be counted as 1, and a person who dedicates 20% of their time to R&D

shall be counted as 0.2. If someone works for three months full-time during the year, s/he will be counted as 0.25, as this is a quarter of the year. If a person works for part of the year full-time, and part of the year part-time, an estimation of the annual dedication to R&D will be calculated with a weighting (if s/he is, for example, 3 months full-time and 9 months 20% dedicated to R&D, then we calculate: 0.25*1 + 0.75*0.2 = 0.4).

1.4 Health research

This refers not only to biomedical research, but also to a broader field that includes R&D as regards health in the social sciences, above all, research in health services, intended to protect and promote human health

The medical sciences include the following scientific fields:

- Basic medicine (anatomy, cytology, physiology, genetics, pharmacy, pharmacology, toxicology, immunology and immuno-haematology, clinical chemistry, clinical microbiology, pathology)
- Clinical medicine (anaesthesia, paediatrics, obstetrics and gynaecology, internal medicine, surgery, odontology, neurology, psychiatry, radiology, therapy, otorhinolaryngology, ophthalmology)
- Health sciences (public health, social medicine, hygiene, nursing, pathology)

Examples of R&D in health

- Research carried out in the fields of **medical sciences** (basic medicine, clinical medicine and health sciences). For example, research in cardiology, respiratory diseases, mental illness, etc.
- There is health research into **biological sciences**, particularly into genetics, the objective of which is human health. For example, cancer research, research into degenerative illnesses, etc.
- -Research into **social and humanitarian sciences**, the objective of which is to protect and improve human health. For example, research into prevention of drug addition
- The research into health and safety in nuclear power stations
- The autopsy carried out in order to study a specific case of mortality, for the purpose of establishing the side effects of a certain cancer treatment. A routine autopsy carried out in order to ascertain the causes of a particular death, responds to current medical practice, and is not considered research
- Clinical trials:

Prior to releasing new medications, vaccinations or treatments on the market, they must be subjected to systematic trials on human volunteers, in order to ensure that they are safe and effective. These clinical trials are divided into four standardised phases, three of which are carried out before permission to manufacture is granted. In order to be able to draw international comparisons, it has been agreed that phases 1, 2 and 3 may be included in R&D. Phase 4 of the clinical trials, in which the medicine or treatment undergoes continued trials following approval and manufacture, must only be included as R&D if it gives rise to scientific or technological advances. Moreover, not all activities carried out before obtaining permission to manufacture are considered R&D, especially when a significant lag in time occurs after finishing phase 3 of the trials, during which marketing and development activities may begin.